ADPT Quote, Financials, Valuation and Earnings

Akero Therapeutics, Inc. has a net margin of 10.16% compared to Adaptive Biotechnologies Corp.'s net margin of --. Adaptive Biotechnologies Corp.'s return on equity of -39.8% beat Akero Therapeutics, Inc.'s return on equity of -32.14%.

Adaptive Biotechnologies Corp. has a consensus price target of $20.29, signalling upside risk potential of 16.18%. On the other hand Akero Therapeutics, Inc. has an analysts' consensus of $56.00 which suggests that it could grow by 2.51%. Given that Adaptive Biotechnologies Corp. has higher upside potential than Akero Therapeutics, Inc., analysts believe Adaptive Biotechnologies Corp. is more attractive than Akero Therapeutics, Inc..

Adaptive Biotechnologies Corp. has a beta of 2.201, which suggesting that the stock is 120.134% more volatile than S&P 500. In comparison Akero Therapeutics, Inc. has a beta of -0.399, suggesting its less volatile than the S&P 500 by 139.855%.

Adaptive Biotechnologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies Corp. pays -- of its earnings as a dividend. Akero Therapeutics, Inc. pays out -- of its earnings as a dividend.

Adaptive Biotechnologies Corp. quarterly revenues are $94M, which are larger than Akero Therapeutics, Inc. quarterly revenues of --. Adaptive Biotechnologies Corp.'s net income of $9.5M is higher than Akero Therapeutics, Inc.'s net income of -$81.6M. Notably, Adaptive Biotechnologies Corp.'s price-to-earnings ratio is -- while Akero Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies Corp. is 10.57x versus -- for Akero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of 10.16% compared to Adaptive Biotechnologies Corp.'s net margin of -82.06%. Adaptive Biotechnologies Corp.'s return on equity of -39.8% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Adaptive Biotechnologies Corp. has a consensus price target of $20.29, signalling upside risk potential of 16.18%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.47%. Given that Adaptive Biotechnologies Corp. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Adaptive Biotechnologies Corp. is more attractive than Ionis Pharmaceuticals, Inc..

Adaptive Biotechnologies Corp. has a beta of 2.201, which suggesting that the stock is 120.134% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Adaptive Biotechnologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies Corp. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Adaptive Biotechnologies Corp. quarterly revenues are $94M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Adaptive Biotechnologies Corp.'s net income of $9.5M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Adaptive Biotechnologies Corp.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies Corp. is 10.57x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 10.16% compared to Adaptive Biotechnologies Corp.'s net margin of 38.89%. Adaptive Biotechnologies Corp.'s return on equity of -39.8% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Adaptive Biotechnologies Corp. has a consensus price target of $20.29, signalling upside risk potential of 16.18%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $768.36 which suggests that it could grow by 6.18%. Given that Adaptive Biotechnologies Corp. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Adaptive Biotechnologies Corp. is more attractive than Regeneron Pharmaceuticals, Inc..

Adaptive Biotechnologies Corp. has a beta of 2.201, which suggesting that the stock is 120.134% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Adaptive Biotechnologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Adaptive Biotechnologies Corp. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Adaptive Biotechnologies Corp. quarterly revenues are $94M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Adaptive Biotechnologies Corp.'s net income of $9.5M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Adaptive Biotechnologies Corp.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies Corp. is 10.57x versus 5.60x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 10.16% compared to Adaptive Biotechnologies Corp.'s net margin of 34.76%. Adaptive Biotechnologies Corp.'s return on equity of -39.8% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Adaptive Biotechnologies Corp. has a consensus price target of $20.29, signalling upside risk potential of 16.18%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $485.36 which suggests that it could grow by 4.8%. Given that Adaptive Biotechnologies Corp. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Adaptive Biotechnologies Corp. is more attractive than Vertex Pharmaceuticals, Inc..

Adaptive Biotechnologies Corp. has a beta of 2.201, which suggesting that the stock is 120.134% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Adaptive Biotechnologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies Corp. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Adaptive Biotechnologies Corp. quarterly revenues are $94M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Adaptive Biotechnologies Corp.'s net income of $9.5M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Adaptive Biotechnologies Corp.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies Corp. is 10.57x versus 10.23x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.